1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Retinal Vein Occlusion - Pipeline Review, H1 2020, provides an overview of the Retinal Vein Occlusion (Ophthalmology) pipeline landscape.
Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of retinal vein occlusion is a sudden painless change in vision. Predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol and age.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Retinal Vein Occlusion - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Retinal Vein Occlusion (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 5, 2, 6 and 2 respectively.
Retinal Vein Occlusion (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Retinal Vein Occlusion (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Retinal Vein Occlusion (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Retinal Vein Occlusion (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Retinal Vein Occlusion (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Retinal Vein Occlusion - Overview
- Retinal Vein Occlusion - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Retinal Vein Occlusion - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Retinal Vein Occlusion - Companies Involved in Therapeutics Development
- 3SBio Inc
- Addmedica SAS
- Annexin Pharmaceuticals AB
- Calpain Therapeutics Pty Ltd
- Chengdu Kanghong Pharmaceuticals Group Co Ltd
- Drive Therapeutics LLC
- EyePoint Pharmaceuticals Inc
- Gene Signal International SA
- Graybug Vision Inc
- Kodiak Sciences Inc
- Kuur Therapeutics Ltd
- Lupin Ltd
- Novartis AG
- Ocular Therapeutix Inc
- Outlook Therapeutics Inc
- Panoptes Pharma GesmbH
- Regeneron Pharmaceuticals Inc
- Ripple therapeutics Corp
- Retinal Vein Occlusion - Drug Profiles
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- aflibercept SR - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- aganirsen - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- ANXV - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- axitinib - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- bevacizumab - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- brolucizumab - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- conbercept - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- D-28P001 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- dexamethasone SR - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- hydroxyurea - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- KSI-301 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- LKA-651 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Monoclonal Antibody to Inhibit VEGF for Ophthalmology and Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- PP-001 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Protein to Inhibit VEGF for Ophthalmology - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Inhibit CAPN1 and CAPN2 for Ischaemic Retinal Vein Occlusion - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- sunitinib malate CR - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- vorolanib - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Retinal Vein Occlusion - Dormant Projects
- Retinal Vein Occlusion - Discontinued Products
- Retinal Vein Occlusion - Product Development Milestones
- Featured News & Press Releases
- Feb 08, 2020: Kodiak Sciences announces additional safety, efficacy and durability data from ongoing phase 1b study of KSI-301 in patients with wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion at the angiogenesis, exudation, and degeneration 2020 meeting
- Feb 05, 2020: Kodiak Sciences announces upcoming presentation of additional KSI-301 phase 1b clinical study data at Angiogenesis, Exudation, and Degeneration 2020 meeting
- Oct 11, 2019: Kodiak Sciences announces safety, efficacy and durability data from ongoing phase 1b study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the American Academy of Ophthalmology Annual Meeting Retina Subspecialty Day
- Oct 07, 2019: Kodiak Sciences announces upcoming presentation of durability data from clinical development program of KSI-301 in Wet AMD, DME, and RVO at American Academy of Ophthalmology 2019 Annual Meeting
- Oct 02, 2019: Graybug Vision initiates Phase 2b (ALTISSIMO) clinical trial of GB-102 in patients with Wet Age-Related Macular Degeneration
- Sep 18, 2019: Graybug Vision initiates clinical trial in macular edema secondary to diabetic macular edema or retinal vein occlusion
- Sep 04, 2019: Kodiak Sciences announces upcoming presentations at EURETINA Meeting
- Jul 29, 2019: Kodiak’s anti-VEGF antibody yields positive data in Phase Ib study
- Jul 24, 2019: Kodiak Sciences announces upcoming presentation at American Society of Retina Specialists (ASRS) 2019 Annual Meeting
- Apr 24, 2019: Interface Biologics to present local drug delivery technology update at Bloom Burton & Co. Healthcare Investor Conference
- Feb 08, 2019: Kodiak Sciences announces upcoming presentation of KSI-301 12-week phase 1a study data at Angiogenesis, Exudation, and Degeneration 2019 Meeting
- Dec 21, 2018: Kodiak Sciences announces completion of 12-week phase 1a study of KSI-301 in patients with diabetic macular edema demonstrating safety and durability of responses following single dose of intravitreal anti-VEGFantibody biopolymer conjugate
- Feb 14, 2012: Gene Signal And Collaborators Demonstrate Successful Activity Of Topical Aganirsen In Models Of Retinal Neovascular Disease
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact
- Disclaimer
List of Tables
- Number of Products under Development for Retinal Vein Occlusion, H1 2020
- Number of Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020 (Contd..1), H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Retinal Vein Occlusion - Pipeline by 3SBio Inc, H1 2020
- Retinal Vein Occlusion - Pipeline by Addmedica SAS, H1 2020
- Retinal Vein Occlusion - Pipeline by Annexin Pharmaceuticals AB, H1 2020
- Retinal Vein Occlusion - Pipeline by Calpain Therapeutics Pty Ltd, H1 2020
- Retinal Vein Occlusion - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H1 2020
- Retinal Vein Occlusion - Pipeline by Drive Therapeutics LLC, H1 2020
- Retinal Vein Occlusion - Pipeline by EyePoint Pharmaceuticals Inc, H1 2020
- Retinal Vein Occlusion - Pipeline by Gene Signal International SA, H1 2020
- Retinal Vein Occlusion - Pipeline by Graybug Vision Inc, H1 2020
- Retinal Vein Occlusion - Pipeline by Kodiak Sciences Inc, H1 2020
- Retinal Vein Occlusion - Pipeline by Kuur Therapeutics Ltd, H1 2020
- Retinal Vein Occlusion - Pipeline by Lupin Ltd, H1 2020
- Retinal Vein Occlusion - Pipeline by Novartis AG, H1 2020
- Retinal Vein Occlusion - Pipeline by Ocular Therapeutix Inc, H1 2020
- Retinal Vein Occlusion - Pipeline by Outlook Therapeutics Inc, H1 2020
- Retinal Vein Occlusion - Pipeline by Panoptes Pharma GesmbH, H1 2020
- Retinal Vein Occlusion - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
- Retinal Vein Occlusion - Pipeline by Ripple therapeutics Corp, H1 2020
- Retinal Vein Occlusion - Dormant Projects, H1 2020
- Retinal Vein Occlusion - Discontinued Products, H1 2020
List of Figures
- Number of Products under Development for Retinal Vein Occlusion, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio Inc
- Addmedica SAS
- Annexin Pharmaceuticals AB
- Calpain Therapeutics Pty Ltd
- Chengdu Kanghong Pharmaceuticals Group Co Ltd
- Drive Therapeutics LLC
- EyePoint Pharmaceuticals Inc
- Gene Signal International SA
- Graybug Vision Inc
- Kodiak Sciences Inc
- Kuur Therapeutics Ltd
- Lupin Ltd
- Novartis AG
- Ocular Therapeutix Inc
- Outlook Therapeutics Inc
- Panoptes Pharma GesmbH
- Regeneron Pharmaceuticals Inc
- Ripple therapeutics Corp
